.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,452,550

« Back to Dashboard

Details for Patent: 7,452,550

Title:Liposomal antineoplastic drugs and uses thereof
Abstract: This invention relates to liposomal antineoplastic agents (e.g., camptothecin) compositions and methods of using such compositions for treating neoplasia and for inhibiting angiogenesis. The compositions and methods are useful for modulating the plasma circulation half-life of an active agent.
Inventor(s): Madden; Thomas D. (Vancouver, CA), Semple; Sean C. (Vancouver, CA), Ahkong; Quet F. (Surrey, CA)
Assignee: Hana Biosciences, Inc. (South San Francisco, CA)
Filing Date:May 09, 2006
Application Number:11/430,522
Claims:1. A method for modulating the plasma circulation half-life of vinorelbine in a subject, comprising: (a) providing a liposomal formulation comprising: a liposome having free vinorelbine in solution and precipitated vinorelbine encapsulated therein; and (b) adding a liposome having no vinorelbine encapsulated therein to the liposomal formulation; wherein the liposome having encapsulated vinorelbine and the liposome having no encapsulated vinorelbine comprise sphingomyelin and cholesterol at a ratio in the range of about 75/25 mol %/mol % sphingomyelinl/cholesterol to about 30/50 mol %/mol % sphingomyelinl/cholesterol, wherein the ratio of the vinorelbine to lipid is 0.2-0.3:1 (w/w), and wherein the precipitated vinorelbine in the liposome is at least 50% of the total vinorelbine in the formulation; and administering the liposomal formulation to the subject, thereby modulating the plasma circulation half-life of vinorelbine in the subject.

2. The method of claim 1, wherein the plasma circulation half-life of the vinorelbine is increased.

3. The method of claim 1, wherein the plasma area under the curve (AUC) of the vinorelbine is increased.

4. The method of claim 1, wherein the serum half-life of the liposome having encapsulated vinorelbine is prolonged.

5. The method of claim 1, wherein the liposome having encapsulated vinorelbine comprises a component that enhances precipitation of the vinorelbine.

6. The method of claim 1, wherein the ratio of liposomes having encapsulated vinorelbine to liposomes having no encapsulated vinorelbine is from 1:0.5 to 1:1000.

7. The method of claim 1, wherein the liposome having encapsulated vinorelbine and the liposome having no encapsulated vinorelbine comprises sphingomyelin and cholesterol in a 55:45 molar ratio.

8. The method of claim 1, wherein the liposome having encapsulated vinorelbine and the liposome having no encapsulated vinorelbine comprises sphingomyelin and cholesterol in a 50:50 molar ratio.

9. The method of claim 1, wherein the ratio of the vinorelbine to lipid is about 0.3:1 (w/w).

10. A method for modulating the plasma circulation half-life of vinorelbine in a subject, comprising: (a) providing a liposomal formulation comprising: a liposome having free vinorelbine in solution and precipitated vinorelbine encapsulated therein; and (b) adding a liposome having no vinorelbine encapsulated therein to the liposomal formulation; wherein the liposome having encapsulated vinorelbine and the liposome having no encapsulated vinorelbine comprise sphingomyelin and cholesterol at a ratio of about 55/45 mol %/mol % sphingomyelinl/cholesterol, wherein the ratio of the vinorelbine to lipid is 0.3:1 (w/w), and wherein the precipitated vinorelbine in the liposome is at least 50% of the total vinorelbine in the formulation; and administering the liposomal formulation to the subject, thereby modulating the plasma circulation half-life of vinorelbine in the subject.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc